Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAVIV: Abexinostat plus Pazopanib in Renal Cell Carcinoma
NCT03592472Phase 3Recruiting
- Sponsor
- Xynomic Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of abexinostat in renal cell carcinoma (RCC), sponsored by Xynomic Pharmaceuticals. Started Jul 2018; status: recruiting.
02
Drugs
abexinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03592472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03592472.